Öztürk, HülyaÖztürk, HayrettinDokucu, Ali İhsanOtçu, Selçuk2021-06-232021-06-2320061784-3227https://hdl.handle.net/20.500.12491/5902https://www.scopus.com/inward/record.uri?eid=2-s2.0-33747621139&partnerID=40&md5=6332cc1fee1ca20417817af1fa1a7542Background and study aims : Extrahepatic cholestasis is one of the main factors causing liver fibrosis. In this study, we aimed to evaluate the effects of lexipafant (BB-882), a platelet activating factor receptor antagonist, on liver damage in rats with bile duct ligation. Methods: A total of 30 male Sprague-Dawley rats weighing 160-190 g were used in this study. Group I (Sham-control, n = 10) rats were undergone laparotomy alone and bile duct was just dissected from the surrounding tissue. Group 2 rats (BDL/Untreated, n = 10) were subjected to bile duct ligation and no drug was applied. Group 3 rats (BDUBB-882, n = 10) received a daily dose of BB-882 intraperitoneally for 14 days after BDL. At the end of the two-week period, biochemical and histological evaluation was processed. Results : The mean serum bilirubin and liver enzymes level significantly decreased, and Superoxide dismutase, catalase and glutathione peroxidase values were significantly increased in BDL/BB-882 group when compared to BDUUntreated group. The histopathological score was significantly less in the BDUBB-882 group compared to the BDL/Untreated rats. In the BDL/BB-882 group was observed less fibrosis and neutrophil infiltration. Conclusions : These results suggest that BB-882 (lexipafant) may reduce the severity of the inflammatory response to liver injury produced by bile duct ligation in rats.eninfo:eu-repo/semantics/closedAccessBile Duct LigationBB-882LexipafantRatArticle692197202169296152-s2.0-33747621139N/AWOS:000240612900003Q4